Complain about a product or service

States Win Refunds for Remeron Users

A New Jersey federal judge has given preliminary approval to a settlement with the attorneys general of all 50 states ensuring that thousands of consumers who paid high prescription prices for the antidepressant drug Remeron will get their money back.

Remeron • Refund Procedure Announced • Class Action Suit Settled

The manufacturer of the drug, Organon USA Inc. of New Jersey, and its Dutch parent company, Akzo Nobel N.V., agreed to settle for $36 million after engaging in a scheme to mislead the U.S. Food and Drug Administration and manipulate the patent process.

This orchestrated practice unlawfully kept cheaper generic equivalents of Remeron off the market, extended the company's monopoly over the drug and wrongly generated millions of dollars in profits, the states charged.

"The company abused the system by preventing Texas consumers from having access to more affordable, generic versions of this drug," said Texas Attorney General Abbott. "My antitrust team led the way in getting justified relief for the end-users of the medication here in Texas and nationwide, and the overall result is lower drug prices."

Consumers, as well as state purchasers such as Medicaid programs, will be among those who may submit claims for reimbursement. The court approval allows attorneys general to implement a claims administration process for consumers who purchased Remeron or a generic equivalent between June 15, 2001, and the present.

Consumers will be notified via advertising in major newspapers and magazines, as well as by direct mail and radio public service announcements from pharmacies and psychiatrists. Beginning in March, the claims administrator will introduce a Web site, www.remeronsettlement.com, and toll-free number for information about filing claims.

Generic equivalents are included for consideration in refunds because Organon's actions delayed their entry into the marketplace, which adversely influenced how quickly the prices might have fallen for Remeron and its generic substitutes.

Organon USA also agreed to an injunction that will require it to make timely listings of patents and prohibits it from submitting false or misleading information to the FDA.

The settlement must receive final court approval before the money will be distributed.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.

Back to the top |

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.